Colorado Cancer Research Program
To keep hope and promise alive by the progress that we help make through community oncology research.
To provide the people of Colorado and southern Wyoming the opportunity to participate in and benefit from the medical research conducted through cancer clinical trials.
To serve as an NCI Community Oncology Research Program (NCORP), as designated by the National Cancer Institute (NCI), to enable the people in our local community to participate in cancer prevention, cancer control, and cancer treatment research through local physicians, community hospitals and clinics.
CCRP began in 1983 as Colorado’s first and only regional and community research organization, an affiliate of the National Cancer Institute (NCI). Since then, their work has resulted in numerous discoveries and breakthroughs that have resulted in a level of rapid progress in cancer control that was never before thought possible. CCRP continues to be a key player in the development and implementation of cutting edge clinical trials as well as innovative treatment protocols that offer patients an entirely new spectrum of options and REAL hope for extending and saving lives. Cancers that were previously a certain death sentence upon diagnosis are now treatable and even survivable. Their work in the field of genomic research has helped to create innovative new approaches and expanded cancer prevention options for those who may have a genetic predisposition for a certain type of cancer, as well as improving symptom control for those who are on a successful track to healing. CCRP partners with hospitals, community clinics and physicians/oncologists throughout Colorado as well as in Wyoming, so that patients have local access in their own communities to cutting edge cancer treatment, symptom control and prevention, rather than having to travel long distances, as they once did---often out of state, to receive such treatments that have the potential of extending and saving their lives.
CCRP Board of Directors
Chair: Norman Benedict, Retired PERA, Denver, CO
Vice Chair: Andrew Nemechek, MD, Surgical Oncologist, Littleton, CO
Secretary: Jerry Hayes, Insurance Broker, Cancer Survivor, Denver, CO
Treasurer: Matt Nyberg, Esq., Attorney, Denver, CO
Past Chair: Nicholas DiBella, MD, Medical Oncologist, Director Emeritus, Aurora, C
- Ken Dawson, (Community Engagement Committee), Retired, Littleton, CO
- Karen Holtman, RN, (Membership Committee) Retired Nurse, Centennial, CO
- R. Lee Jennings, MD, (Quality Committee) Retired Surgical Oncologist, Greenwood Village, CO
- Madeleine Kane, MD, PhD, Medical Oncologist, Aurora, CO
- Ann Murphy, PhD, (Audit and Finance Committees) College Dean, Arvada, CO
- Dianne Primavera, Executive Director, Komen Society, Cancer Survivor, Denver, CO
- Patricia L. Peterson, B.S.N., J.D. President/CEO, CCRP, Denver, CO
- Keren Sturtz, MD, Principal Investigator, CCRP, Denver, CO
Institutional Review Board (IRB)
What Is an Institutional Review Board (IRB)?
An IRB is an independent committee designated by an organization to assure that the rights and welfare of people participating in research studies are protected. Colorado Cancer Research Program has designated the Colorado Community IRB (CCIRB) to review the research studies it participates in, whether sponsored by the National Cancer Institute or other sponsors.
Who Serves on an IRB?
An IRB consists of at least five members of varying backgrounds. IRB members have the professional experience to provide appropriate scientific and ethical review. An IRB must have at least one scientist member and at least one member whose primary experience is non-scientific. There must also be members from the community, representing both gender and racial diversity. The members of the Colorado Community IRB include retired physicians (cancer specialists) and legal, educational, and research professionals, as well as cancer patients.
Where Does an IRB Get Its Authority?
In 1974, the US Department of Health and Human Services created regulations regarding the protection of human subjects through the establishment of IRBs, which are overseen on the federal level by the HHS Office for Human Research Protections (OHRP). OHRP assists IRBs in their work and receives and investigates claims of inappropriate research practices.
How Does an IRB Make Its Decisions?
Before a physician researcher can enroll patients in a research study, the protocol (research procedures) is reviewed by the IRB. The researcher provides the IRB with all the necessary materials to conduct a review, including a full description of the proposed project and treatment drugs, other materials to be used such as questionnaires, a description of the manner in which subjects will be enrolled, and a detailed consent form. The IRB examines all these materials to determine if the research participants are adequately informed and protected.
What Does an IRB Do after Reviewing the Project?
After examining the materials the researcher provides to the IRB, the committee members must decide if the benefits of the research are maximized and the risks minimized, and make a final determination on whether the benefits justify the risks to the participants. If the IRB finds that this is the case, they may approve the study. Alternatively, the IRB may request that the researcher make specific changes to the procedures or consent form and then approve the protocol contingent on these changes. Finally, the IRB may decide to disapprove the project. In addition to reviewing new research protocols, IRBs also review continuing projects or those that have changes in their procedures. Continuing projects are reviewed yearly or more often if the IRB feels it is necessary.